Cargando…

The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study

SIMPLE SUMMARY: Programmed death 1 (PD1)/programmed death ligand-1 (PD-L1) inhibitor is the standard therapy for advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers. However, the suitable therapy after the progression of anti-PD1/PD-L1 for MSI/dMMR gas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Mifen, Wang, Zhenghang, Liu, Zimin, Liu, Ning, Fang, Weijia, Zhang, Hangyu, Jin, Xuan, Li, Jiayi, Zhao, Weifeng, Qu, Huajun, Song, Fanghua, Chang, Zhiwei, Li, Yi, Tang, Yong, Xu, Chunlei, Zhang, Xiaotian, Wang, Xicheng, Peng, Zhi, Cai, Jinping, Li, Jian, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601260/ https://www.ncbi.nlm.nih.gov/pubmed/36291942 http://dx.doi.org/10.3390/cancers14205158

Ejemplares similares

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
por: Wang, Yujiao, et al.
Publicado: (2022)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
por: Zhuo, Na, et al.
Publicado: (2022)

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma
por: Wang, Zhenghang, et al.
Publicado: (2022)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2021)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
por: Jiao, Xi, et al.
Publicado: (2021)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer
por: Lu, Zhihao, et al.
Publicado: (2019)

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
por: Wang, Yanni, et al.
Publicado: (2021)

Immune checkpoints in MSI and CSI colorectal cancers and their translational implications
por: Llosa, Nicolás J, et al.
Publicado: (2013)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

Comparing DESI-MSI and MALDI-MSI Mediated Spatial Metabolomics and Their Applications in Cancer Studies
por: He, Michelle Junyi, et al.
Publicado: (2022)

Colorectal Carcinogenesis: MSI-H Versus MSI-L
por: Pawlik, Timothy M., et al.
Publicado: (2004)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
por: Gallois, Claire, et al.
Publicado: (2023)

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
por: Lu, Zhihao, et al.
Publicado: (2020)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis
por: Xu, Ting, et al.
Publicado: (2023)

Knockout of RNA Binding Protein MSI2 Impairs Follicle Development in the Mouse Ovary: Characterization of MSI1 and MSI2 during Folliculogenesis
por: Sutherland, Jessie M., et al.
Publicado: (2015)

The Musashi proteins MSI1 and MSI2 are required for photoreceptor morphogenesis and vision in mice
por: Sundar, Jesse, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Drosophila Rbp6 Is an Orthologue of Vertebrate Msi-1 and Msi-2, but Does Not Function Redundantly with dMsi to Regulate Germline Stem Cell Behaviour
por: Siddall, Nicole A., et al.
Publicado: (2012)

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
por: Sahin, Ibrahim Halil, et al.
Publicado: (2019)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

High‐throughput MALDI‐MSI metabolite analysis of plant tissue microarrays
por: Huang, Hangjun, et al.
Publicado: (2023)

Transformation of the intestinal epithelium by the MSI2 RNA binding protein
por: Wang, Shan, et al.
Publicado: (2015)

An innovative single‐base extension method for synchronous detection of point mutations and MSI status in colorectal cancer
por: Liang, Li, et al.
Publicado: (2022)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Semiallogenic fusions of MSI(+ )tumor cells and activated B cells induce MSI-specific T cell responses
por: Garbe, Yvette, et al.
Publicado: (2011)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

msiDBN: A Method of Identifying Critical Proteins in Dynamic PPI Networks
por: Zhang, Yuan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9gsq9sdd0e4j3uk0d8fa6g0a9q